The impact of therapeutic-dose induced intestinal enrofloxacin concentrations in healthy pigs on fecal Escherichia coli populations.
Administration, Oral
Animals
Anti-Bacterial Agents
/ pharmacology
Drug Resistance, Bacterial
/ drug effects
Enrofloxacin
/ administration & dosage
Escherichia coli
/ drug effects
Feces
/ chemistry
Female
Gastrointestinal Contents
/ chemistry
Injections, Intramuscular
/ veterinary
Male
Microbial Sensitivity Tests
/ veterinary
Sus scrofa
Administration route
Antimicrobial resistance
Antimicrobials
Dose
Enrofloxacin
Escherichia coli
Microbiota
Journal
BMC veterinary research
ISSN: 1746-6148
Titre abrégé: BMC Vet Res
Pays: England
ID NLM: 101249759
Informations de publication
Date de publication:
08 Oct 2020
08 Oct 2020
Historique:
received:
17
12
2019
accepted:
02
10
2020
entrez:
9
10
2020
pubmed:
10
10
2020
medline:
1
5
2021
Statut:
epublish
Résumé
Knowledge of therapy-induced intestinal tract concentrations of antimicrobials allows for interpretation and prediction of antimicrobial resistance selection within the intestinal microbiota. This study describes the impact of three different doses of enrofloxacin (ENR) and two different administration routes on the intestinal concentration of ENR and on the fecal Escherichia coli populations in pigs. Enrofloxacin was administered on three consecutive days to four different treatment groups. The groups either received an oral bolus administration of ENR (conventional or half dose) or an intramuscular administration (conventional or double dose). Quantitative analysis of fecal samples showed high ENR concentrations in all groups, ranging from 5.114 ± 1.272 μg/g up to 39.54 ± 10.43 μg/g at the end of the treatment period. In addition, analysis of the luminal intestinal content revealed an increase of ENR concentration from the proximal to the distal intestinal tract segments, with no significant effect of administration route. Fecal samples were also screened for resistance in E. coli isolates against ENR. Wild-type (MIC≤0.125 μg/mL) and non-wild-type (0.125 < MIC≤2 μg/mL) E. coli isolates were found at time 0 h. At the end of treatment (3 days) only non-wild-type isolates (MIC≥32 μg/mL) were found. In conclusion, the observed intestinal ENR concentrations in all groups showed to be both theoretically (based on pharmacokinetic and pharmacodynamic principles) and effectively (in vivo measurement) capable of significantly reducing the intestinal E. coli wild-type population.
Sections du résumé
BACKGROUND
BACKGROUND
Knowledge of therapy-induced intestinal tract concentrations of antimicrobials allows for interpretation and prediction of antimicrobial resistance selection within the intestinal microbiota. This study describes the impact of three different doses of enrofloxacin (ENR) and two different administration routes on the intestinal concentration of ENR and on the fecal Escherichia coli populations in pigs. Enrofloxacin was administered on three consecutive days to four different treatment groups. The groups either received an oral bolus administration of ENR (conventional or half dose) or an intramuscular administration (conventional or double dose).
RESULTS
RESULTS
Quantitative analysis of fecal samples showed high ENR concentrations in all groups, ranging from 5.114 ± 1.272 μg/g up to 39.54 ± 10.43 μg/g at the end of the treatment period. In addition, analysis of the luminal intestinal content revealed an increase of ENR concentration from the proximal to the distal intestinal tract segments, with no significant effect of administration route. Fecal samples were also screened for resistance in E. coli isolates against ENR. Wild-type (MIC≤0.125 μg/mL) and non-wild-type (0.125 < MIC≤2 μg/mL) E. coli isolates were found at time 0 h. At the end of treatment (3 days) only non-wild-type isolates (MIC≥32 μg/mL) were found.
CONCLUSIONS
CONCLUSIONS
In conclusion, the observed intestinal ENR concentrations in all groups showed to be both theoretically (based on pharmacokinetic and pharmacodynamic principles) and effectively (in vivo measurement) capable of significantly reducing the intestinal E. coli wild-type population.
Identifiants
pubmed: 33032597
doi: 10.1186/s12917-020-02608-9
pii: 10.1186/s12917-020-02608-9
pmc: PMC7545837
doi:
Substances chimiques
Anti-Bacterial Agents
0
Enrofloxacin
3DX3XEK1BN
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
382Subventions
Organisme : FOD Volksgezondheid, Veiligheid van de Voedselketen en Leefmilieu
ID : RF 14/6287 DOSERESIST
Références
Pharmacotherapy. 2001 Oct;21(10 Pt 2):233S-252S
pubmed: 11642690
Vet J. 2006 Jul;172(1):10-28
pubmed: 16154368
Antimicrob Agents Chemother. 2008 Aug;52(8):2992-3
pubmed: 18490500
J Clin Invest. 2014 Oct;124(10):4212-8
pubmed: 25271726
BMC Vet Res. 2014 Dec 02;10:289
pubmed: 25440469
Br J Pharmacol. 1999 Aug;127(7):1728-34
pubmed: 10455332
Curr Pharm Des. 2016;22(26):4069-85
pubmed: 26935702
Antimicrob Agents Chemother. 2013 Jul;57(7):3072-7
pubmed: 23612192
Curr Opin Microbiol. 2009 Oct;12(5):476-81
pubmed: 19716760
J Antimicrob Chemother. 2017 Jul 1;72(7):1991-2001
pubmed: 28419236
J Appl Microbiol. 2003;94(6):1087-97
pubmed: 12752819
Pharmacol Toxicol. 1997 May;80(5):246-50
pubmed: 9181604
Prev Vet Med. 2009 Mar 1;88(3):185-92
pubmed: 19041147
Am J Med Sci. 1996 Jan;311(1):9-16
pubmed: 8571988
J Appl Microbiol. 2017 Nov;123(5):1312-1320
pubmed: 28799283
Appl Environ Microbiol. 2007 Aug;73(15):4785-90
pubmed: 17557857
Antimicrob Agents Chemother. 1996 Oct;40(10):2380-6
pubmed: 8891148
Res Vet Sci. 2003 Dec;75(3):185-93
pubmed: 13129666
Pathol Biol (Paris). 1989 May;37(5):346-9
pubmed: 2780092
Microbiology (Reading). 2010 Nov;156(Pt 11):3216-3223
pubmed: 20705661
J Chemother. 2004 Jun;16 Suppl 3:1-19
pubmed: 15334827
BMC Vet Res. 2016 Sep 20;12:209
pubmed: 27645697
Nat Commun. 2015 Sep 22;6:8292
pubmed: 26392213
Int J Pharm. 2006 Apr 26;313(1-2):175-80
pubmed: 16529884
Int J Antimicrob Agents. 2017 Dec;50(6):707-714
pubmed: 28668685
Can Vet J. 2010 Aug;51(8):853-61
pubmed: 21037885
Appl Microbiol Biotechnol. 2011 Nov;92(3):479-97
pubmed: 21904817
J Antimicrob Chemother. 2004 Jan;53(1):28-52
pubmed: 14657094
Drugs. 1999;58 Suppl 2:65-70
pubmed: 10553709
J Vet Pharmacol Ther. 2002 Oct;25(5):335-42
pubmed: 12423223
Int J Antimicrob Agents. 2013 Nov;42(5):429-35
pubmed: 24021905
Microb Drug Resist. 2015 Feb;21(1):50-8
pubmed: 25098762
Environ Toxicol Pharmacol. 2008 Nov;26(3):272-7
pubmed: 21791374
Infect Immun. 1988 May;56(5):1030-5
pubmed: 3281898
Pharm Res. 1998 Mar;15(3):371-6
pubmed: 9563065
Front Microbiol. 2015 Dec 09;6:1355
pubmed: 26696975
Anal Chim Acta. 2012 Dec 5;756:37-48
pubmed: 23176738
Mol Biol Evol. 2017 May 1;34(5):1029-1039
pubmed: 28087782
FEMS Microbiol Rev. 2011 Sep;35(5):901-11
pubmed: 21707669
BMC Vet Res. 2017 Dec 4;13(1):378
pubmed: 29202759
Chemosphere. 2011 Mar;82(10):1408-14
pubmed: 21159362
Environ Sci Technol. 2010 Jan 15;44(2):580-7
pubmed: 20025282
Expert Rev Anti Infect Ther. 2008 Oct;6(5):733-50
pubmed: 18847409
J Pharmacol Exp Ther. 1994 May;269(2):496-502
pubmed: 8182517
J Antimicrob Chemother. 2012 Oct;67(10):2438-44
pubmed: 22685162